|
Steiner G. Fibrates in the metabolic syndrome and in diabetes [J]. Endocrinology and Metabolism Clinics of North America, 2004.545.doi: 10.1016/j.ecl.2004.04.002.
|
|
Expert Panel on Detection. Evaluation and Treatment of high blood cholesterol in adults, Executive summary of the third report of the national cholesterol education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of high blood cholesterol in adults.(Adult Treatment Panel Ⅲ) [J]. the Journal of the American Medical Association, 2001, (19):2486.doi: 10.1001/jama.285.19.2486.
|
|
Barter P. Is high-density lipoprotein the protector of the cardiovascular system [J]. European Heart Journal, 2004, (zA):19.
|
|
Prueksaritanont T, Tang C, Qiu Y. Effects of fibrates on metabolism of statins in human hepatocytes [J]. Drug Metabolish Disposition, 2002, (11):1280.
|
|
Vu-Dac N, Gervois P, Jakel H. apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferators-activated receptor alpha activators [J]. Journal of Biological Chemistry, 2003, (20):17982.doi: 10.1074/jbc.M212191200.
|
|
Fruchart J C. Peroxisome proliferators-activated receptor-alpha activation and high-density lipoprotein metabolism [J]. American Journal of Cardiology, 2001.24N.doi: 10.1016/S0002-9149(01)02149-X.
|
|
Steiner G. The use of fibrates and of statins in preventing atherosclerosis in diabetes [J]. Current Opinion in Lipidology, 2001, (6):611.doi: 10.1097/00041433-200112000-00003.
|
|
Neil A, Wheeler F, Cull J T. Combination statin and fibrate therapy in type 2 diabetes from the lipids in diabetes study [J]. DIABETES, 2003, (z1):A74.
|
|
Ballantyne C M, Olsson A G, Cook T J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S [J]. CIRCULATION, 2001, (25):3046.doi: 10.1161/hc5001.100624.
|
|
Steiner G. The use of fibrates and of statins in preventing atherosclerosis in diabetes [J]. Current Opinion in Lipidology, 2001, (6):611.doi: 10.1097/00041433-200112000-00003.
|
|
Backman J T, Kyrklund C, Neuvomen M. Gemfibrozil greatly incresases plasma concentrations of cerivastatin [J]. Clinical Pharmacology & Therapeutics, 2002.685.
|
|
Kyrklund C, Backman J T, Kivisto K T. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate [J]. Clinical Pharmacology & Therapeutics, 2001, (5):340.doi: 10.1067/mcp.2001.115542.
|
下载:
苏公网安备 32100302010246号
